Anbio Biotechnology (NNNN)

Revenue by Segment

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Surgical & Medical Equipment	8.65M	8.19M	6.71M	23.54M	4.43M
Total	8.65M	8.19M	6.71M	23.54M	4.43M

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
European Union	5.15M	5.62M	4.66M	20.30M	4.09M
Asia Pacific	1.52M	509.17K	73.40K	3.19M	-
North America	296.20K	110.51K	215.44K	50.00K	337.50K
South America	269.54K	1.48M	1.65M	-	-
Other Regions	1.41M	472.38K	111.05K	-	-
Total	8.65M	8.19M	6.71M	23.54M	4.43M

Data Source: S&P Global Market Intelligence Last updated: Dec 31, 2025

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Aug 15, 2026

Data Sources Report a data error